2026
preprint
OpenAlex
Maëlle Batardière, Myriam Iliana Ibanez-Rios, Abdelhakim Khellaf, Elham Dianati et autres
ABSTRACT Intraductal papillary mucinous neoplasms (IPMNs) are cystic precursors of pancreatic ductal adenocarcinoma undergoing dynamic epithelial and stromal remodeling during progression. In this study, we integrated computational pathology, cyclic immunofluorescence, and Xenium spatial transcriptomics to define the spatial organization of the IPMN …
ca, fr, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Kevin Neil, Samuel Génier, Julie Douchin, Hugo Giguère et autres
BACKGROUND: Checkpoint inhibitors revolutionized cancer treatment by potentiating antitumor immune responses. However, many patients do not respond to these therapies, often due to the lack of a pre-existing immune response against cancer cells. Developing immunotherapies that promote cancer-cell antigen recognition, and the …
ca
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Louis-Emmanuel Chriqui, Z Maged, Etienne Abdelnour‐Berchtold, Hasna Bouchaab et autres
Abstract Background Neoadjuvant chemo-immunotherapy has become a standard for management of resectable stage III non-small cell lung cancer (NSCLC) patients with improved overall survival. Post-induction radiological re-staging, commonly performed with CT scan, is crucial in surgical planning. Aims This study evaluates the …
ch
(code pays fourni par la source)
2022
article
OpenAlex
Louis-Emmanuel Chriqui, Yameng Hao, Matteo Ortolini, Christophe Gattlen et autres
Abstract Objective Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Recently, dual immune checkpoint inhibition therapy (ICI) showed improved patient survival. However, only a fraction of patients were responsive to immunotherapy. One potential mechanism of MPM resistance to …
ch
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Christophe Gattlen, Yameng Hao, Melina Gonzalez, Thorsten Krueger et autres
Abstract Objective Immune checkpoint inhibition (ICI) therapy has revolutionized the outcome of certain cancers such as malignant pleural mesothelioma (MPM). However, patient responsiveness to this treatment remains unpredictable. Recently, a role for the gut microbiota composition has emerged for patients to generate …
ch
(code pays fourni par la source)